Tag: Dr. Nazli Azimi
Bioniz Therapeutics announces positive data from BNZ-1 phase 1/2 trial in rCTCL
Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). ... Read More